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Purpose: To evaluate local recurrence (LR) in women with early breast cancer (BC) who 
underwent intraoperative radiation therapy with electrons particles (IORT-E) or adjuvant 
hypofractionated external radiotherapy (HYPOFX).
Materials and methods: We retrospectively analyzed 470 patients with early BC 
treated at our center from September 2009 to December 2012. 235 women were 
treated with breast-conserving surgery and immediate IORT-E (21 Gy/1 fraction) while 
235 patients underwent wide excision followed by hypofractionated whole-breast irradi-
ation. Radiotherapy modality was chosen according to an individualized decision based 
on tumor features, stage, technical feasibility, age, and acceptance to be enrolled in the 
IORT-E group.
results: After a median follow-up of 6 years, we observed 8 (3.4%) and 1 (0.42%) LR 
in the IORT-E and in the HYPOFX group (p = 0.02), respectively. The two groups differed 
in the prevalence of clinical characteristics (p < 0.05): age, tumor size, surgical margins, 
receptors, ki67, and histology. 4 and 1 woman in the IORT-E and HYPOFX group died 
of BC, respectively (p  =  0.167). OS and DFS hazard ratio [HR] were 2.14 (95% IC, 
1.10–4.15) and 2.09 (95% IC, 1.17–3.73), respectively.
conclusion: Our comparison showed that IORT-E and HYPOFX are two effective 
radiotherapy modalities after conservative surgery in early BC. However, at 6 years a 
significant higher rate of LR occurred in patients submitted to IORT-E with respect to 
HYPOFX. This finding may be correlated to some subsets of patients who, depending 
on the biological characteristics of the BC, may be less suitable to IORT-E.
Keywords: early breast cancer, intraoperative radiotherapy, external beam radiotherapy, whole-breast irradiation, 
accelerated partial breast irradiation
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inTrODUcTiOn
Breast cancer (BC) is the most common cancer in women. The 
increasing use of mammographic screening enables an early 
diagnosis to be made in most cases. Conservative surgery is the 
procedure of choice in the management of early-stage BC, and 
all guidelines indicate whole-breast radiotherapy as a part of 
conservative treatment.
The administration of 50 Gy in 25 fractions over 5 weeks to 
the whole breast was considered the standard until a few years 
ago, when the publication of the long-term results of important 
British and Canadian randomized studies proved the effective-
ness and efficiency of schemes administered over shorter times 
(hypofractionated radiotherapy) (1, 2).
Furthermore, in the past 10 years, the possibility of treating 
only the tumor bed has been analyzed, as ipsilateral breast tumor 
recurrences (IBTR) developed in and around the tumor bed in 
44–86% of cases (3), and treatment of the rest of the breast might 
be unnecessary. Indeed, by limiting irradiation to the area of 
potential recurrence by means of partial breast irradiation (PBI), 
much of the surrounding tissues (including the lung, heart, 
uninvolved ipsilateral breast) could be spared, thereby reducing 
toxicity and improving the cosmetic outcome (4, 5).
Several techniques of PBI exist: brachytherapy (intracavitary 
and interstitial approaches), external beam radiation using 
either three-dimensional conformal radiotherapy or intensity 
modulated radiation therapy, and proton radiation. However, all 
these procedures involve the use of several radiation fractions, 
requiring the patients to attend the Radiotherapy Department on 
several days.
This difficulty can be overcome by another PBI modality, 
namely intraoperative radiation therapy with an electron beam 
(IORT-E), which selectively treats the breast volume in which 
the tumor was located by delivering a single dose of radiation 
at the time of surgery, after complete removal of the tumor. This 
procedure reduces treatment time and, potentially, improves the 
patient’s quality of life.
Here, we present a retrospective comparison between two 
treatment modalities used in our center: the single administration 
of 21 Gy by means of IORT-E, and whole-breast irradiation (WBI) 
according to a hypofractionated external radiotherapy (HYPOFX) 
(39 Gy delivered in 13 fractions over 3 weeks to the whole breast, 
plus an individualized concomitant boost to the tumor bed up 
to 42–43 Gy) (6). The comparison was made on 470 consecutive 
women with early BC, who were treated from 2009 to 2012 with 
either IORT-E or HYPOFX. This comparison was prompted by 
our observations over a median follow-up of more than 6 years. 
The women analyzed in this research displayed the same patient 
and tumor characteristics before surgery. Our aims were to 
evaluate the clinical outcomes of these two modalities in a large 
series of patients, and to better understand how to select women 
for the best adjuvant radiotherapy.
MaTerials anD MeThODs
Patients were selected for either IORT-E or HYPOFX accord-
ing to a multidisciplinary discussion involving mainly radio-
oncologists and breast surgeons. The radiotherapy modality was 
chosen according to an individualized decision based on the 
clinical features of the tumor, stage, breast size, technical feasibil-
ity of IORT-E, age, and patients’ willingness to be enrolled in the 
IORT-E group.
Patients were informed that IORT-E was an investigational 
modality (Clinical Trial. Gov NCT01276938) approved by Ethics 
Committee of IRCCS Policlinico San Martino Hospital of Genoa 
(approval number OR09.001), while hypofractionated radio-
therapy was the common practice in breast adjuvant therapy in 
our institution.
iOrT-e Modality
We analyzed the treatments and their results in 235 consecu-
tive patients who underwent wide excision (with sentinel node 
biopsy) followed by IORT with electron particles (IORT-E) to 
the tumor bed as the sole radiation modality between September 
2009 and December 2012. Patients signed an informed consent 
form specifying the pros and cons of IORT-E.
Patient Selection
At the time of patient selection (2009) there were no ASTRO and 
ESTRO selection criteria yet. The candidates for IORT-E were iden-
tified in accordance with the criteria of the American Brachytherapy 
Society and American Society of Breast Surgeons (>50 years), T less 
than 2 cm, pN0, infiltrating ductal carcinoma or ductal carcinoma 
in situ, and microscopically negative margins (>2 mm) (7), regard-
less of the biological features of the tumor. However, publication of 
the ESTRO and ASTRO criteria prompted us to implement more 
restrictive patient selection (8, 9). The characteristics of patients 
treated with IORT-E are summarized in Table 1.
Surgery
The patients treated underwent wide excision with negative 
margins (5 mm) and negative sentinel node biopsy (no axillary 
dissection was performed). Most patients underwent wide exci-
sion with negative margins; in seven patients margins were found 
close or positive, due to discrepancies between initial intraopera-
tive pathology evaluation on the frozen section, and the results on 
the definitive examination on the fixed section. In nine patients, 
lymph node micro-invasion was detected in the definitive histo-
logical examination performed after surgery. After lumpectomy, 
the wide mobilization of the mammary gland, from the fascia of 
the pectoralis major and from the skin allows preparation of the 
clinical target volume to be treated.
To spare the underlying healthy tissue (muscle, rib, lung, and 
heart), a dedicated disk of lead and aluminum is inserted into the 
space between the gland and the pectoral muscle.
Abbreviations: IBTR, ipsilateral breast tumor recurrences; PBI, partial breast 
irradiation; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity 
modulated radiation therapy; IORT-E, intraoperative radiation therapy with an 
electron beam; WBI, whole-breast irradiation; HYPOFX, hypofractionated exter-
nal radiotherapy; CTV, clinical target volume; LIAC, mobile linear accelerators; 
PTFE, polytetrafluoroethylene; MOSFET, metal-oxide-semiconductor field-effect 
transistor; OARs, organs at risk; LADCA, left anterior descending coronary artery; 
LR, local recurrence; DFS, disease-free survival; OS, overall survival.
TaBle 1 | Characteristics of patients in intraoperative radiation therapy with an 
electron beam (IORT-E) group and HYPOFX group.
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technology S.p.A., Italy). This accelerator is equipped with perspex 
cylindrical applicators of different diameters (from 4 to 10 cm). 
An applicator of an appropriate diameter is selected according 
to the size of the tumor, the length of the incision, and the size 
of the breast. The median applicator diameter was 6 cm (range, 
4–7 cm). Mobile LIAC deliver electrons at different nominal ener-
gies: 4–6–8–10 MeV. The appropriate beam energy is chosen on 
the basis of gland thickness, as estimated in at least three different 
points. Moreover, to avoid superficial under-dosage due to dose 
build-up at the beam entrance (−5.4%: 4 MeV; −5.6%: 6 MeV; 
−3.1%: 8 MeV; −0.7%: 10 MeV), we prefer to use nominal beam 
energies higher than 8 MeV. Thus, therapeutic ranges for 5 cm 
applicator diameter are: 4 MeV: 12 mm, 6 MeV: 15 mm, 8 MeV: 
20 mm, and 10 MeV: 26 mm.
Intraoperative radiation therapy with an electron beam 
minimizes the dose to the normal surrounding tissues, owing 
to the dose deposition characteristics of the electron beam, and 
thoracic wall irradiation can be limited by inserting a steel- 
polytetrafluoroethylene (PTFE) (3 mm + 3 mm) shielding plate 
between the deep side of the residual breast gland and the pectoral 
muscle; the plate diameter must be at least 1 cm (preferably 2 cm) 
greater than the diameter of the applicator (10).
Dosimetry and Quality Assurance of IORT-E Delivery
Linear accelerator Linac was calibrated by means of a Fricke 
dosimeter in inter-comparison with two plane-parallel ion cham-
bers (11). MicroMOSFET 502-RDM (Best Medical Canada Ltd.) 
detectors were employed to monitor the exit dose, defined as 
the dose at the deepest part of the target: detectors are placed 
inside a thin, sterile catheter (6Fr closed-end brachytherapy 
catheter), and fixed to the center of the PTFE side of the shield-
ing disk before insertion into the breast. To perform treatment, 
optimized monitor units were compared by means of the method 
described by Agostinelli et al. (12): irradiation is split into two 
phases in order to allow an appropriate action level so as to re-
check the relative position between the applicator and shielding 
disk or to correct the dose if the first metal-oxide semiconductor 
field-effect transistor (MOSFET) reading is higher than 10%. In 
this case, the second phase of irradiation is performed by using 
self-normalization in order to cover 95% of the volume with 95% 
of the prescribed dose suggested by Agostinelli et al. (12).
hypofractionated external radiotherapy 
(hYPOFX)
We analyzed the treatment and results of 235 consecutive 
patients with the same clinical characteristics as those of the 
IORT-E group. The HYPOFX group underwent wide excision 
followed by hypofractionated WBI, which was planned and 
delivered during the same period (2009–2012) (6). Table 1 sum-
marizes the characteristics of patients treated with HYPOFX.
HYPOFX patients received 39 Gy, which was delivered to the 
whole breast in 3-Gy fractions over 3 weeks; they also received a 
concomitant boost dose of 3–4 Gy, which was delivered in 3–4 
fractions to the lumpectomy cavity once a week. Four fractions 
per week is the schedule commonly used in our Department in 
order to optimize clinical activities and Linac quality control. On 
the basis of the Linear-Quadratic model, we assumed that 39 Gy 
A sterile applicator is introduced through the skin incision 
and placed directly in contact with the breast target. To prevent 
herniation, a film is applied to the breast tissue at the far end of 
the applicator (10).
Radiotherapy Technique
A single dose of 21 Gy, prescribed at 90% of the isodose was deliv-
ered by a dedicated linear accelerator (LIAC–SIT Sordina IORT 
TaBle 3 | Mortality rate in intraoperative radiation therapy with an electron beam 
(IORT-E) group and in HYPOFX group.
iOrT-e (n = 235) hYPOFX (n = 235) p Value
Died of breast cancer 4 (1.7) 1 (0.4) 0.167
Died of other causes 19 (8.1) 11 (4.7) 0.133
Overall death 23 (9.8) 12 (5.1)
Data are numbers (%). Chi-square test.
TaBle 2 | Characteristics of patients who developed ipsilateral breast tumor 
recurrences (IBRT) in intraoperative radiation therapy with an electron beam 
(IORT-E) group and in HYPOFX group.
histology T (mm) grade er% Pgr% Ki67% her2
IORT-E LCI 12 G2 92 4 2 0
LCI 16 G2 96 95 28 0
DCI 18 G3 99 84 83 0
DCI 25 G3 12 0 27 3+
DCI 15 G2 97 6 24 0
DCI 15 G2 99 83 36 0
DCI 13 G3 99 45 82 1+
DCI 25 G3 92 85 34 1+
HYPOFX MUCINOUS 9 G2 97 97 26 1+
FigUre 1 | Kaplan–Meier estimates of the cumulative probability of ipsilateral 
recurrence.
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in 3 Gy fractions was equivalent to 50 Gy in 2.0 Gy fractions. This 
radiotherapy schedule had previously been tested in clinics, and 
preliminary results were published in 2010 (6). The procedures of 
treatment planning have been described previously (6).
In the planning phase, the patient was positioned on a wing-
board and a computerized tomography (CT GE Lightspeed 
Ultra) scan was performed. Four tattoos were created in order 
to properly position the patient during each treatment session.
Whole-breast irradiation was performed by means of 3D 
conformal radiation therapy with tangential beams and sub-fields 
to reduce hotspots (preferably not more than 105% of the whole-
breast prescription dose). Irradiation of the boost volume was 
carried out with two or three fields, not necessarily with the same 
tangential-field isocenter. Organs at risk (OARs) were shielded by 
using an MLC collimator. For plan optimization, we considered 
OARs dose constraints for the ipsilateral lung, heart, and left 
anterior descending coronary artery.
We optimized boost planning in plan sum (whole-breast plan 
plus boost plan) in order to reduce the margins of boost fields.
cOMParisOn enDPOinTs
The primary endpoint of this comparative matched analysis was 
to evaluate local recurrence (LR) rates at 6 years in pts who had 
undergone intraoperative radiation therapy and in pts treated 
with hypofractionated external radiotherapy. Secondary end-
points were overall survival (OS) and disease-free survival (DFS) 
rates for the two different radiotherapy modalities.
sTaTisTical MeThODs
The cumulative incidence of LR and OS plots and DFS were 
drawn by means of the Kaplan–Meier analysis method. The 
log-rank test was used to assess the difference between patients 
treated with intraoperative radiation therapy and patients treated 
with hypofractionated external radiotherapy. Multivariable Cox 
proportional hazard regression was used to adjust the hazard 
ratios of LR between the groups for demographic and disease 
characteristics. Statistical analysis was performed by means of 
MedCalc 17.9.7 (MedCalc Software, Ostend, Belgium).
resUlTs
After a median follow-up of 6.1 (5.4–7.0) years in the IORT-E group 
and 6.0 (5.4–7.7) years in the HYPOFX group, we observed local 
relapses in 3.4% (8/235) of IORT-E patients and 0.42% (1/235) of 
HYPOFX patients (p = 0.0192) (Figure 1). All eight patients who 
developed IBTR during follow-up had adverse biological risk 
factors: high histological grade, ki67 value >20, invasive lobular 
carcinoma (Table  2). No patient with a luminal A tumor suf-
fered relapsed. Only one patient relapsed in the HYPOFX group 
(Table 2). A total of 23 IORT-E pts and 12 HYPOFX pts died. Of 
the IORT-E patients who died, 4 (17%) died of BC and 19 (83%) 
of other causes: three of heart disease, six of a second tumor, three 
of non-cancer-related causes, and seven of factors related to age 
(60% were aged >70  years). Of the 12 HYPOFX patients who 
died, only one (8%) died of BC and 11 (92%) of other causes: one 
of brain ischemia, one of cholangiocarcinoma, one of pancreatic 
cancer, one of Parkinson’s disease, two of heart failure, and five of 
age-related factors (Table 3).
As shown by the Chi-Square test, the difference between the 
mortality rates in the two groups was not significant. We used the 
log-rank test to analyze OS and DFS in the two groups: differences 
in both OS and DFS between the two groups were significant only 
on unadjusted analysis (Table 4). Figures 2A,B shows DFS and OS.
DiscUssiOn
In recent years, various strategies have been introduced in order 
to optimize patients’ quality of life and healthcare system 
TaBle 4 | Unadjusted and adjusted hazard ratios (HRs) in patients treated with intraoperative radiation therapy with an electron beam (IORT-E) compared with 
HYPOFX.
Unadjusted adjusted
hr p Value hr p Value
Ipsilateral breast tumor recurrences recurrence 8.0231 (2.0000–32.1844) 0.0192 6.2216 (0.6432–60.1769) 0.1144
Overall survival 2.1387 (1.1014–4.1528) 0.0274 0.9320 (0.4255–2.0414) 0.8603
Disease-free survival 2.0934 (1.1734–3.7346) 0.0138 1.0436 (0.5256–2.0644) 0.9024
FigUre 2 | The disease-free survival and overall survival (OS) using Kaplan–Meier method. (a) Disease-free survival, (B) OS.
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resources. PBI and the use of hypofractionated schemes are 
among the most studied and applied options.
In comparison with other PBI techniques, IORT offers the 
advantage of being delivered during surgery, with the possibility 
to directly visualize the target, thereby maximizing the precision 
of dose delivery to the target volume and sparing surrounding 
healthy tissue (breast, lung, heart, and skin).
Administering radiation treatment during surgery improves 
the quality of life of patients, as they do not have to attend the 
radiotherapy center to receive many fractions of external beam 
radiation (10). Furthermore, from a radiobiological point of 
view, the radiation dose is delivered before tumor cells have a 
chance to proliferate, when the tissues are richly vascularized, 
which potentially makes them more sensitive to the action of the 
radiation (oxygen effect) (13).
Our analysis compared IORT-E treatment with hypofrac-
tionated radiation therapy administered in the same period 
to consecutive patients with early BC. The outcomes may be 
interesting as, to our knowledge, no similar data have been 
published. One randomized controlled trial compared IORT-E 
with a standard radiotherapy schedule (50 Gy in 25 fractions). 
However, although hypofractionated radiotherapy is considered 
the standard of care in early BC in most centers, no phase III trial 
has compared PBI with this shortened fractionated regimen. 
Thus, the widespread adoption of hypofractionated radiation 
therapy, which is strongly supported by literature data (ASTRO), 
should prompt radio-oncologists to compare hypofractionated 
radiation therapy with PBI such as IORT-E.
In our analysis of 470 patients, we detected a statistically sig-
nificant difference in IBTR between the IORT-E and HYPOFX 
groups (3.4 vs 0.4%; p = 0.0192). We are aware that patients in 
HYPOFX group presented higher biological risk factors (high 
histological grade, ki67 value >20, invasive lobular carcinoma—
Table  2), despite this IBRT was lower than in IORT-E group. 
This could be partly explained by the fact that these patients 
underwent to WBI with an additional higher boost dose of 4 Gy, 
concomitantly delivered to the lumpectomy cavity, with a con-
sequent high dose delivered to the whole breast that might have 
reduce the LR rate.
Moreover this is a retrospective non-randomized comparison 
in patients treated in the same period of time and assigned to 
undergo IORT-E HYPOFX on the basis of technical feasibility 
or patient preference, despite all these limits the outcomes 
may provide preliminary suggestions for the choice of the best 
radiotherapy technique (IORT-E vs HYPOFX). Interestingly, 
we observed that all eight patients who developed IBTR in the 
IORT-E group had adverse biological risk factors: high histologi-
cal grade, ki67 value >20, and invasive lobular carcinoma, while 
no patients with a luminal A tumor suffered relapse. Not all the 
IORT-E patients analyzed underwent tru-cut biopsy before sur-
gery, since the procedure has only recently become a standard of 
care and, as reported by several authors, an aggressive biological 
subtype is a strong predictor of disease relapse (14–16). For this 
reason, the IORT-E group included a large number of high-grade 
tumors and not luminal A. These aggressive characteristics are 
significantly correlated with the likelihood to develop LR; on this 
basis we strongly underline that a preliminary tru-cut biopsy is 
deeply indicated.
Only after the publication of the ASTRO and ESTRO consensus 
statements the eligibility criteria for PBI selection become more 
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accurate. Moreover, some patients were assigned to the IORT-E 
group on account of their poor general condition or the presence 
of diseases, including psychiatric conditions that did not allow 
any other treatment. These issues may explain the higher rate of 
IBTR in the IORT-E group.
Researchers from The European Oncology Institute (IEO), 
Milan, Italy, who are leading experts in IORT-E, have described 
their retrospective experiences in several papers (14–18), in 
which they analyzed the various procedures and discussed their 
results in the light of the criteria set out in the ASTRO and ESTRO 
consensus statements (19, 20).
Analysis of their data reveals that the 5-year rate of ipsilateral 
BC recurrence is certainly higher in the “unsuitable” and “cau-
tionary” ASTRO categories than in the “suitable” category (8.8; 
4.4; and 1.5%, respectively) (p = 0.0003) (19).
The results of the ELIOT randomized trial, published in 2013 
by Veronesi et al., show a higher rate of IBTR in the intraoperative 
radiotherapy group than in the external standard radiotherapy 
group: the 5-year event rate for IBRT was 4.4% (95% CI 2·7–6·1) 
in the former and 0.4% (0·0–1·0) in the latter (21). These data 
seem to be comparable to ours. Even if it is not a randomized 
study, the results obtained in our analysis, are consistent with 
the European Institute of Oncology randomized data (Veronesi 
et al.) (21).
Silverstein discussed the results of the ELIOT study on clas-
sifying the patients into low- and high-risk groups on the basis of 
tumor size, receptor status, nodal positivity, and grade. Low-risk 
women (69.4% of ELIOT patients) had a 5-year IBTR rate of only 
1.5%, as opposed to 11.3% in the 30.6% of ELIOT patients with 1 
or more high-risk factors.
As confirmed by previous findings (19), proper selection for 
IORT-E is mandatory (22).
With regards to EBRT, in our department we have progres-
sively introduced several hypofractionated schemes, considering 
the results of British and Canadian trials. Analysis of 10-year 
results of the UK START trials confirms that an appropriate 
hypofractionated radiotherapy schedule is safe and effective in 
women with early BC; furthermore, normal tissue effects, such 
as breast shrinkage, telangiectasia, and breast edema, were sig-
nificantly less common in the hypofractionated group than in 
the standard group. These results suggest that the administration 
of 40  Gy delivered in 15 fractions should be continued, and a 
hypofractionated 3-week schedule has already been adopted by 
most UK centers as the standard adjuvant radiotherapy (2).
The data from the START trials are in agreement with those 
from the Canadian study.
The Ontario trial showed that local tumor control and cos-
metic breast cancer results were no worse with a hypofraction-
ated scheme (42.5 Gy in 16 fractions over 3.2 weeks) than with 
standard treatment (50 Gy in 25 fractions over 5 weeks). The risk 
of LR at 10  years was 6.7% in the standard-treatment patients 
and 6.2% in the hypofractionated regimen. Both in the control 
group and in the hypofractionated group, the majority of patients 
achieved a good or excellent esthetic outcome (71.3 and 69.8%) 
(23). Moreover, hypofractionated RT can improve patients’ qual-
ity of life by reducing access to the center, to accelerate patient 
turnover, and to save healthcare resources.
In our Hypofx WBI group, we recorded a 0.42% local relapse 
rate (1/235 pts). This datum is extremely interesting, as it confirms 
literature data and demonstrates that our schedule is similarly 
effective and safe. The improved techniques enabled by new 
advanced linear accelerators, and better OAR contouring, allow 
toxicity to be reduced, particularly the high level of cardiotoxicity 
in pts who undergo hypofractionated radiotherapy treatment on 
the left side (24).
cOnclUsiOn
Our analysis demonstrated that the IORT-E technique is effica-
cious; the most important finding is that, in some subsets of 
patients, it may be equivalent than other techniques. Indeed, 
patient selection must be rigorous, in that the benefit yielded by 
this treatment depends on the biological characteristics of the 
tumor. In those patients who are suitable for IORT-E (i.e., high 
estrogen receptor, low ki67 index, and low grade), the technique 
can be suggested and the pros and cons of the single-dose therapy 
discussed with the patient, not least with regards to the better 
quality of life offered by this procedure.
Moreover, this investigation confirms that the adjuvant hypof-
ractionated scheme is a favorable and well-tolerated strategy that 
provides excellent local control. In pts who present unfavorable 
biological characteristics on tru-cut, this approach may be better.
Only a randomized comparison between IORT-E and 
HYPOFX could confirm our suggestions and estimate the level 
of evidence and the strength of recommendation of IORT vs 
hypofractionated regimens in clinical practice.
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